Repurposing the selective estrogen receptor modulator bazedoxifene to suppress gastrointestinal cancer growth.
Saved in:
| Title: | Repurposing the selective estrogen receptor modulator bazedoxifene to suppress gastrointestinal cancer growth. |
|---|---|
| Authors: | Thilakasiri P; Olivia Newton-John Cancer Research Institute, School of Cancer Medicine, La Trobe University, Heidelberg, Vic., Australia., Huynh J; Olivia Newton-John Cancer Research Institute, School of Cancer Medicine, La Trobe University, Heidelberg, Vic., Australia., Poh AR; Olivia Newton-John Cancer Research Institute, School of Cancer Medicine, La Trobe University, Heidelberg, Vic., Australia., Tan CW; The Walter and Eliza Hall Institute, Melbourne, Vic., Australia., Nero TL; ACRF Rational Drug Discovery Centre, St Vincent's Institute, Melbourne, Vic., Australia.; Department of Biochemistry and Molecular Biology, Bio21 Institute, University of Melbourne, Melbourne, Vic., Australia., Tran K; Olivia Newton-John Cancer Research Institute, School of Cancer Medicine, La Trobe University, Heidelberg, Vic., Australia., Parslow AC; Olivia Newton-John Cancer Research Institute, School of Cancer Medicine, La Trobe University, Heidelberg, Vic., Australia.; Department of Molecular Imaging and Therapy, Austin Health, Melbourne, Vic., Australia., Afshar-Sterle S; Olivia Newton-John Cancer Research Institute, School of Cancer Medicine, La Trobe University, Heidelberg, Vic., Australia., Baloyan D; Olivia Newton-John Cancer Research Institute, School of Cancer Medicine, La Trobe University, Heidelberg, Vic., Australia., Hannan NJ; Department of Obstetrics and Gynaecology, University of Melbourne, Melbourne, Vic., Australia., Buchert M; Olivia Newton-John Cancer Research Institute, School of Cancer Medicine, La Trobe University, Heidelberg, Vic., Australia., Scott AM; Olivia Newton-John Cancer Research Institute, School of Cancer Medicine, La Trobe University, Heidelberg, Vic., Australia.; Department of Molecular Imaging and Therapy, Austin Health, Melbourne, Vic., Australia.; Department of Medicine, University of Melbourne, Melbourne, Vic., Australia., Griffin MD; Department of Biochemistry and Molecular Biology, Bio21 Institute, University of Melbourne, Melbourne, Vic., Australia., Hollande F; Department of Clinical Pathology, University of Melbourne Centre for Cancer Research, Victorian Comprehensive Cancer Centre, University of Melbourne, Melbourne, Vic., Australia., Parker MW; ACRF Rational Drug Discovery Centre, St Vincent's Institute, Melbourne, Vic., Australia.; Department of Biochemistry and Molecular Biology, Bio21 Institute, University of Melbourne, Melbourne, Vic., Australia., Putoczki TL; The Walter and Eliza Hall Institute, Melbourne, Vic., Australia., Ernst M; Olivia Newton-John Cancer Research Institute, School of Cancer Medicine, La Trobe University, Heidelberg, Vic., Australia matthias.ernst@onjcri.org.au ashwini.chand@onjcri.org.au., Chand AL; Olivia Newton-John Cancer Research Institute, School of Cancer Medicine, La Trobe University, Heidelberg, Vic., Australia matthias.ernst@onjcri.org.au ashwini.chand@onjcri.org.au. |
| Source: | EMBO molecular medicine [EMBO Mol Med] 2019 Apr; Vol. 11 (4). |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: EMBO Press Country of Publication: Germany NLM ID: 101487380 Publication Model: Print Cited Medium: Internet ISSN: 1757-4684 (Electronic) Linking ISSN: 17574676 NLM ISO Abbreviation: EMBO Mol Med Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
